Literature DB >> 29587290

Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature.

Julia Benzel1,2,3, Volker Fendrich1,4.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma is one of the most lethal types of cancer with a 5-year survival rate of around 7%. Due to the relatively poor prognosis, the potential need of an effective chemoprevention is highly needed.
SUMMARY: Different risk factors like smoking or hereditary tumour syndromes should be known for early detection of pancreatic intraepithelial neoplasia. Chemopreventive dietary agents include curcumin, capsaicin and flavonoid, whereas potential chemopreventive drugs compromise aspirin, metformin or statins. This review aims to give an overview on potential risk factors for the development of pancreatic cancer. Furthermore, we try to summarise known chemopreventive agents to support the fight against this lethal disease. Key Messages: On the one hand, there are natural agents that exhibit preventive properties and can lead to the prohibition of pancreatic cancer. On the other hand, there are drugs and agents that are currently used in other contexts and are thus already approved and studied in terms of their mechanisms of effects and the related secondary effects.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Aspirin; Capsaicin; Chemoprevention; Pancreatic ductal adenocarcinoma; Pancreatic intraepithelial neoplasia; Pancreatitis; Smoking

Mesh:

Substances:

Year:  2018        PMID: 29587290     DOI: 10.1159/000485741

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  6 in total

1.  Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  Min-Seok Seo; Jina Yeo; In Cheol Hwang; Jae-Yong Shim
Journal:  Clin Rheumatol       Date:  2019-07-03       Impact factor: 2.980

2.  Efficacy and Pharmacokinetic Considerations of Loratadine Nanoformulations and its Combinations for Pancreatic Cancer Chemoprevention.

Authors:  Preshita Desai; Kevin Zhijun Wang; David Ann; Jeffrey Wang; Sunil Prabhu
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

3.  DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer.

Authors:  Hiroyuki Kato; Aya Naiki-Ito; Shugo Suzuki; Shingo Inaguma; Masayuki Komura; Kenju Nakao; Taku Naiki; Kenta Kachi; Akihisa Kato; Yoichi Matsuo; Satoru Takahashi
Journal:  Carcinogenesis       Date:  2021-07-16       Impact factor: 4.944

4.  Commentary: Blood-Derived microRNAs for Pancreatic Cancer Diagnosis: A Narrative Review and Meta-Analysis.

Authors:  Rama Jayaraj; Chellan Kumarasamy; Shanthi Sabarimurugan; Siddhartha Baxi
Journal:  Front Physiol       Date:  2019-01-22       Impact factor: 4.566

5.  Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer.

Authors:  Robert G Goetze; Soeren M Buchholz; Ning Ou; Qinrong Zhang; Shilpa Patil; Markus Schirmer; Shiv K Singh; Volker Ellenrieder; Elisabeth Hessmann; Qing-Bin Lu; Albrecht Neesse
Journal:  Cells       Date:  2019-06-09       Impact factor: 6.600

6.  ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer.

Authors:  Nikhil Gupta; Jung Eun Park; Wilford Tse; Jee Keem Low; Oi Lian Kon; Neil McCarthy; Siu Kwan Sze
Journal:  Oncotarget       Date:  2019-10-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.